NCT01971242View on ClinicalTrials.gov

Trial of Exenatide for Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

August 31, 2016

Conditions
Parkinson's Disease
Interventions
DRUG

Exenatide

2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide

OTHER

Placebo

Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.

Trial Locations (1)

WC1N 3BG

National Hospital for Neurology & Neurosurgery (part of UCLH NHS Trust), London

All Listed Sponsors
lead

University College, London

OTHER

NCT01971242 - Trial of Exenatide for Parkinson's Disease | Biotech Hunter | Biotech Hunter